Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.87+0.15 (+4.03%)
Close on Nov 13, 2026Market cap $143.89MP/E –Yield –
Armata Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Armata Pharmaceuticals's cash was $18.32M at Sep 30, 2026. For fiscal 2025 it was $8.69M, down 41.2% from the year before. Over ten years it grew -0.8% a year on average. The highest annual figure on record is $20.81M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.69M | -41.2% |
| FY2024 | Dec 31, 2024 | $14.77M | -23.2% |
| FY2023 | Dec 31, 2023 | $19.24M | -7.5% |
| FY2022 | Dec 31, 2022 | $20.81M | +81.2% |
| FY2021 | Dec 31, 2021 | $11.49M | +5.9% |
| FY2020 | Dec 31, 2020 | $10.85M | +61.1% |
| FY2019 | Dec 31, 2019 | $6.73M | -35.6% |
| FY2018 | Dec 31, 2018 | $10.46M | -14.8% |
| FY2017 | Dec 31, 2017 | $12.28M | +139.2% |
| FY2016 | Dec 31, 2016 | $5.13M | -45.2% |
| FY2015 | Dec 31, 2015 | $9.37M | +42.4% |
| FY2014 | Dec 31, 2014 | $6.58M | -67.7% |
| FY2013 | Dec 31, 2013 | $20.36M | +2261.4% |
| FY2012 | Dec 31, 2012 | $862.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.32M | +24.1% |
| Q2 FY2026 | Jun 30, 2026 | $23.95M | +453.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.75M | -59.3% |
| Q4 FY2025 | Dec 31, 2025 | $8.69M | -41.2% |
| Q3 FY2025 | Sep 30, 2025 | $14.76M | -13.9% |
| Q2 FY2025 | Jun 30, 2025 | $4.33M | -83.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.69M | -69.1% |
| Q4 FY2024 | Dec 31, 2024 | $14.77M | -23.2% |
| Q3 FY2024 | Sep 30, 2024 | $17.14M | -28.5% |
| Q2 FY2024 | Jun 30, 2024 | $26.41M | +112.0% |
| Q1 FY2024 | Mar 31, 2024 | $37.86M | +50.8% |
| Q4 FY2023 | Dec 31, 2023 | $19.24M | -7.5% |
| Q3 FY2023 | Sep 30, 2023 | $23.96M | -5.6% |
| Q2 FY2023 | Jun 30, 2023 | $12.46M | -66.3% |
| Q1 FY2023 | Mar 31, 2023 | $25.11M | -45.9% |
| Q4 FY2022 | Dec 31, 2022 | $20.81M | +81.2% |
| Q3 FY2022 | Sep 30, 2022 | $25.38M | +110.2% |
| Q2 FY2022 | Jun 30, 2022 | $36.98M | +110.9% |
| Q1 FY2022 | Mar 31, 2022 | $46.41M | +106.7% |
| Q4 FY2021 | Dec 31, 2021 | $11.49M | +5.9% |
| Q3 FY2021 | Sep 30, 2021 | $12.08M | -24.0% |
| Q2 FY2021 | Jun 30, 2021 | $17.54M | -11.4% |
| Q1 FY2021 | Mar 31, 2021 | $22.46M | -7.2% |
| Q4 FY2020 | Dec 31, 2020 | $10.85M | +61.1% |
| Q3 FY2020 | Sep 30, 2020 | $15.89M | +82.8% |
| Q2 FY2020 | Jun 30, 2020 | $19.79M | +50.0% |
| Q1 FY2020 | Mar 31, 2020 | $24.21M | +292.9% |
| Q4 FY2019 | Dec 31, 2019 | $6.73M | -35.6% |
| Q3 FY2019 | Sep 30, 2019 | $8.69M | -35.1% |
| Q2 FY2019 | Jun 30, 2019 | $13.19M | -14.5% |
| Q1 FY2019 | Mar 31, 2019 | $6.16M | -24.9% |
| Q4 FY2018 | Dec 31, 2018 | $10.46M | -14.8% |
| Q3 FY2018 | Sep 30, 2018 | $13.39M | +73.4% |
| Q2 FY2018 | Jun 30, 2018 | $15.42M | +72.1% |
| Q1 FY2018 | Mar 31, 2018 | $8.21M | +272.7% |
| Q4 FY2017 | Dec 31, 2017 | $12.28M | +139.2% |
| Q3 FY2017 | Sep 30, 2017 | $7.73M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.96M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.13M | – |
See a number that looks wrong?